AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02296541 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA CON-S env
Description: Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
Study NCT02296541 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA Mosaic env
Description: Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
Study NCT02296541 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MVA-CMDR
Description: Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
Study NCT03873662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
Study NCT03228615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDM Intervention
Description: Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
Study NCT00938015 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: This is a non-interventional study
Study NCT03029754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive leg raise
Description: A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
Study NCT03359278 — intervention group
Intervention type: PROCEDURE
Intervention: open reduction and internal fixation
Description: The volar approach was used for open reduction and internal fixation of distal radius fractures
Study NCT05324839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: injecting different dosage to different group
Study NCT00727675 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrated Cognitive Behavioral Therapy
Description: CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
Study NCT03506334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVBT using Dynesys System Components
Description: Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
Study NCT03506334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine fusion
Description: Children with scoliosis undergoing fusion surgery will form the control arm
Study NCT04180956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bias-reduction Intervention
Description: A training for doctors
Study NCT03170544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: 20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
Study NCT03170544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
Study NCT03170544 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
Study NCT03170544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
Study NCT02934126 — intervention group
Intervention type: OTHER
Intervention: breast cancer patients
Description: semi structured face to face interviews
Study NCT03503565 — intervention group
Intervention type: PROCEDURE
Intervention: intraoperative neuromuscular blockade
Description: The intensity of intraoperative neuromuscular blockade
Study NCT04358809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of heat killed (autoclaved) Mycobacterium w
Description: Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
Study NCT04358809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo along with Standard of care (SOC) treatment for COVID-19
Study NCT03024294 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy
Description: To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
Study NCT04088227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Patients will receive platelet rich plasma injection two times prior to surgery.
Study NCT04088227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
Study NCT01725100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212B (Standard DMSO content)
Description: Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
Study NCT01725100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212B (Lower DMSO content)
Description: Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
Study NCT02163759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
Study NCT02163759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
Study NCT02163759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
Study NCT02163759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study NCT02163759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study NCT02163759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study NCT03626337 — intervention group
Intervention type: DRUG
Intervention: Thiamine 100 MG/ML
Description: 100 mg thiamine provided as intramuscular injection
Study NCT00845559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
Study NCT02910895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tumor biopsy
Description: biopsy
Study NCT06690086 — intervention group
Intervention type: PROCEDURE
Intervention: Lesion biopsy
Description: Lesions enrolled in the study are biopsied to confirm histopathology
Study NCT06690086 — intervention group
Intervention type: DEVICE
Intervention: DermaSensor Device Use
Description: Users are blinded to the DermaSensor Device result
Study NCT00308854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy
Study NCT00308854 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic Therapy
Study NCT01365364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Physical Exercise
Description: All individuals were submitted to physical exercise reaching maximum effort
Study NCT00673777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT00348673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061
Description: Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
Study NCT00348673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061
Description: Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
Study NCT01663012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Study NCT04505332 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthroplasty
Description: back pain in orthopedists due to working actively and performing arthroplasty every day
Study NCT02012660 — intervention group
Intervention type: OTHER
Intervention: Seasonality
Description: The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
Study NCT01284023 — intervention group
Intervention type: OTHER
Intervention: Shaving
Description: Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
Study NCT02907684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
Study NCT02907684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Muffins/Crackers
Description: Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation.
Study NCT04177979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Near-assisted learning through trained peers
Description: Students randomly allocated to this group were overseen during sessions by trained peer instructors.
Study NCT00946790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
Study NCT00946790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
Study NCT01594619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Oral 25mg tablet
Study NCT01594619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Oral 25mg tablet
Study NCT04960371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: coronary flow reserve (CFR)
Description: Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler. We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg. min) for 2 min. The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity. All patients abstained from caffeine-containing drinks for at least 24h before testing.
Study NCT03843060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
Study NCT03843060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
Study NCT00879255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy Group Videoteleconference
Description: Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.
Study NCT01647802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing attempts with the Turner Device
Description: Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
Study NCT01594619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem XR
Description: Oral 240mg tablet
Study NCT02366832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 17g Galil Medical Ice Sphere cryoablation needle
Description: Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
Study NCT02218333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: 4 dl milk will be consumed daily with breakfast and supper for 12 weeks
Study NCT02218333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01863329 — intervention group
Intervention type: PROCEDURE
Intervention: retrobulbar ultrasound
Description: both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
Study NCT02755220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingularbio® Aortic valve replacement
Description: the patients will be replaced by Cingularbio heart valve
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 100Mg Oral Cap
Description: giving a drug to relieve post-dural puncture headache
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Giving drug to relieve post-dural puncture headache
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: giving a drug to relieve post-dural puncture headache
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: giving a drug to relieve post-dural puncture headache
Study NCT03910088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral fluids
Description: giving oral fluids to maintain good hydration
Study NCT03910088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral fluids
Description: giving oral fluids to maintain good hydration
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: giving a drug to relieve post-dural puncture headache
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: giving a drug to relieve post-dural puncture headache
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: giving a drug to relieve post-dural puncture headache
Study NCT03910088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac
Description: giving a drug to relieve post-dural puncture headache
Study NCT04679974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melodic-based Communication Therapy
Description: General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word
Study NCT02155920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
Study NCT01647802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing attempts with the Tina device
Description: Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
Study NCT03226925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanically-assisted ventilation
Description: Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
Study NCT03226925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic MRI acquisition
Description: Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
Study NCT03226925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Planning 4D-CT
Description: In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
Study NCT02564978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
Study NCT03658733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
Study NCT03658733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.